Harshit Jain, MD, is Founder & Global CEO of Doceree.getty​There is a meeting that I've seen happen at some point in every major pharma company. The meeting has a room full of smart, experienced marketers, slides loaded with data and dashboards open on three screens. Somewhere in the middle of it all, someone asks a question that should have a straightforward answer—what is actually working? The room goes quiet; not because people don't care, but because no one fully trusts the numbers in front of them. I have sat in enough of those rooms to know this isn't an isolated problem.Why Marketing Never Got Its Moment​Think about how the modern enterprise was built. Finance gained a unified view of global operations through ERP platforms like SAP. HR moved beyond spreadsheets and institutional memory as systems like Workday became trusted systems of record. Sales evolved from a function driven largely by relationships and intuition into one managed with consistent data and workflows as platforms like Salesforce brought CRM into the mainstream.​Each of these transformations followed the same pattern: a fragmented function, a mounting cost of chaos and one infrastructure moment that changed everything—not by adding more tools, but by creating a foundational layer that unified how work gets done. Pharma marketing has never had that moment. It remains one of the most complex, high-stakes marketing environments and one of the least unified. Brands are typically managed in silos, agencies operate in parallel without a shared view, data lives in disconnected platforms, and the people responsible for billion-dollar decisions are often doing so without a source of truth they collectively trust. The Category Failure No One Wants To Name This is not a technology failure. The industry has spent aggressively on technology, and yet the outcomes tell a different story. Total domestic healthcare marketing spend reached $22.4 billion in 2022, yet only 16% of patients believed healthcare communications were trustworthy. The spending happened, but the clarity never came. That is because the industry has been solving for capability when the real gap has always been coordination. Every new tool added power to one part of the system and complexity to the whole. The result is a marketing tech stack that is impressively broad and operationally fragmented. What it seems that pharma marketing never demanded (and therefore never received) was a foundational layer; a system that didn't just collect data but connected decisions and gave every stakeholder, from brand manager to agency partner to medical reviewer, a shared operational reality. Not An Abstract CostThe consequences of running without that foundation are real. Research from a global study of over 1,000 marketers found that 26% of marketing budgets are wasted on ineffective channels and misaligned strategies.In pharma, where campaign cycles are long, regulatory requirements are stringent and the cost of a delayed or misaligned launch is measured in millions, that inefficiency compounds fast. It shows up in slow market activation, briefs that get rewritten four times and post-campaign reviews where no one can agree on what the numbers mean. The waste is not visible on any balance sheet, but every senior marketer reading this has felt it. However, something is changing, and this time the industry may finally be ready to listen. ​Why This Moment Is Different The conditions that prevented pharma marketing's infrastructure moment from arriving earlier—data fragmentation, regulatory caution and organizational inertia—are shifting. AI-driven intelligence is making unified decision-making genuinely possible at scale. A post-pandemic generation of marketing leaders has a higher tolerance for structural change and a lower tolerance for operational chaos. And perhaps most importantly, the competitive pressure to move faster, prove ROI more clearly and align more tightly across functions is no longer optional. Infrastructure moments in any industry are only obvious in hindsight. The leaders who recognized them in real time—who understood that the next advantage wasn't another capability, but a better foundation—are the ones who shaped what came after. I believe pharma marketing is at that exact inflection point today. ​​Leading The Change​The industry has the data and talent, and it has accumulated enough frustration with fragmentation to finally demand something better. What it has lacked is the collective willingness to stop normalizing operational silos and start treating marketing as a coordinated enterprise function rather than a collection of disconnected tools and teams.The organizations that strategize for that shift first will do more than improve operational efficiency. They will set a new standard for how pharma marketing is planned, measured and executed.​​Forbes Technology Council is an invitation-only community for world-class CIOs, CTOs and technology executives. Do I qualify?